This year, in a response to the Covid-19 pandemic, the Lister Institute was keen to award as many Fellowships as possible and, for the first time, eight researchers will each receive £250,000.
With the funding, Dr Amarnath, an investigator in the BRC’s Skin and Oral Diseases theme, will research immune checkpoint therapies to help skin cancer patients and identify why the majority currently do not respond to treatments.
Dr Amarnath said:
“I am thrilled for receiving the Lister Prize. It will enable my laboratory to pursue an important research area that could redefine the immune landscape in melanoma. “We believe this work will directly contribute to enhanced patient stratification strategies for checkpoint therapies in skin cancers. “Our work relies on novel resources; technologies such as spatial transcriptomics, BD Rhapsody single cell protein and transcriptomics analysis that will be primarily supported by this award.”
“I am thrilled for receiving the Lister Prize. It will enable my laboratory to pursue an important research area that could redefine the immune landscape in melanoma.
“We believe this work will directly contribute to enhanced patient stratification strategies for checkpoint therapies in skin cancers.
“Our work relies on novel resources; technologies such as spatial transcriptomics, BD Rhapsody single cell protein and transcriptomics analysis that will be primarily supported by this award.”
Read the full story here